Summer 2026 - Computational Biology Internship at Bristol-Myers Squibb

San Diego, California, United States

Apply Now

Not SpecifiedCompensation

InternshipExperience Level

InternshipJob Type

UnknownVisa

Pharmaceuticals, BiotechnologyIndustries

Requirements

Master's or PhD level student currently enrolled in a MS/PhD program in computer science, bioinformatics, statistics, physics, or a similar field
Experience in programming with Python or R, as well as common statistical modeling / machine learning frameworks in the corresponding language
Familiarity with network analysis / systems biology methods as applied to multi-omics data (e.g., transcriptomics / proteomics)
Must be able to work full-time for the 10-week program duration (June - August 2026)
Excellent verbal and communication skills
Authorized to work in the US both at the time of hire and for the duration of employment (no immigration or visa sponsorship available)

Responsibilities

Analyze internal and public multi-omics/perturbation datasets to uncover biomarker and pathway signatures relevant to mechanism and response
Build reproducible R/Python pipelines; implement and benchmark published methods where appropriate
Integrate orthogonal evidence (e.g., network/pathway context, sequence/structure features, prior knowledge graphs) to increase confidence in findings
Develop simple prioritization/scorecards to nominate hypotheses (e.g., candidate combinations or multi-target strategies)
Communicate results via clear figures, notebooks, and brief readouts to cross-functional partners

Skills

Computational Biology

Multi-Omics

Perturbational Data

Drug Synergy

Combination Therapies

Precision Medicine

Data Analysis

Omics Datasets

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free